Compass Ion Advisors LLC Makes New Investment in Akebia Therapeutics, Inc. (NASDAQ:AKBA)

Compass Ion Advisors LLC bought a new position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 25,095 shares of the biopharmaceutical company’s stock, valued at approximately $46,000.

A number of other large investors have also bought and sold shares of AKBA. Citigroup Inc. increased its position in Akebia Therapeutics by 311,608.2% in the third quarter. Citigroup Inc. now owns 152,737 shares of the biopharmaceutical company’s stock worth $174,000 after buying an additional 152,688 shares during the last quarter. Raymond James & Associates grew its position in shares of Akebia Therapeutics by 48.0% in the fourth quarter. Raymond James & Associates now owns 29,917 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 9,696 shares in the last quarter. Sapient Capital LLC purchased a new position in shares of Akebia Therapeutics in the fourth quarter valued at $248,000. Mackenzie Financial Corp grew its position in shares of Akebia Therapeutics by 37.6% in the fourth quarter. Mackenzie Financial Corp now owns 23,159 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 6,330 shares in the last quarter. Finally, Archer Investment Corp purchased a new position in shares of Akebia Therapeutics in the fourth quarter valued at $25,000. 33.92% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on AKBA shares. StockNews.com cut Akebia Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 29th. HC Wainwright lifted their price target on Akebia Therapeutics from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Thursday, March 28th.

Akebia Therapeutics Stock Performance

NASDAQ:AKBA opened at $0.99 on Tuesday. The firm has a market capitalization of $208.43 million, a price-to-earnings ratio of -4.32 and a beta of 0.78. Akebia Therapeutics, Inc. has a 52-week low of $0.78 and a 52-week high of $2.48. The stock has a fifty day moving average of $1.15 and a 200 day moving average of $1.39.

Akebia Therapeutics (NASDAQ:AKBA) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). The business had revenue of $32.61 million for the quarter, compared to the consensus estimate of $41.13 million. During the same period in the prior year, the business posted ($0.14) EPS. Equities analysts forecast that Akebia Therapeutics, Inc. will post -0.28 earnings per share for the current fiscal year.

Akebia Therapeutics Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.